Massimo Di Nicola

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors.

Journal: Journal for immunotherapy of cancer

Published: April 18, 2026

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

New Perspectives and Open Issues in the Adjuvant and Neoadjuvant Treatment of Melanoma.

Journal: Cancers

Published: April 14, 2026

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

ECM-Induced IL-23 Drives Immune Suppression in Breast Cancer via Regulating PD-1 on Tregs.

Journal: Journal of experimental & clinical cancer research : CR

Published: May 12, 2025

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.

Journal: Journal for immunotherapy of cancer

Published: June 14, 2024

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.

Journal: Scientific reports

Published: November 06, 2023

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Journal: Clinical and translational science

Published: October 11, 2023

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: February 05, 2022

Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer.

Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer.

Journal: Cancers

Published: June 30, 2021

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.

The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.

Journal: Targeted oncology

Published: May 16, 2021

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.

Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.

Journal: Journal for immunotherapy of cancer

Published: May 08, 2021

Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?

Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?

Journal: Critical reviews in oncology/hematology

Published: March 15, 2021

Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.

Anticancer innovative therapy congress: Highlights from the 10th anniversary edition.

Journal: Cytokine & growth factor reviews

Published: February 01, 2021

Showing 1-12 of 57

Last Updated: 09/26/2026